Ibugrip Plus 200 mg / 30 mg x 20 film tablets.

Ibugrip Plus 200 mg / 30 mg x 20 compr. movie.

Benefits of Ibugrip Plus 200 mg / 30 mg:

Ibugrip Plus contains two active substances: ibuprofen, which has anti-inflammatory, analgesic and antipyretic action (reduces fever); pseudoephedrine hydrochloride, which has a decongestant action for the upper respiratory tract and sinuses.

Ibugrip Plus is recommended to be used to treat symptoms associated with flu or cold, such as: muscle pain, joint pain, headache, fever, accompanied by nasal congestion (sinusitis, rhinosinusitis).

Doses and method of administration:

Adults, adolescents and children over 12 years of age:

The recommended initial dose is 1-2 film-coated tablets. If necessary, the treatment will continue with 1 or 2 film-coated tablets every 4-6 hours. The maximum recommended dose is 6 film-coated tablets in 24 hours (1200 mg ibuprofen).

Children under 12 years of age:

It is not administered to children under 12 years of age and weighing under 40 kg.

Task

The medicine should not be administered during pregnancy, considering that: - inhibition of prostaglandin synthesis by ibuprofen may have a negative influence on pregnancy and/or embryonic/fetal development.

suckling

Administration of the drug to breastfeeding women is contraindicated because:

- ibuprofen is excreted in breast milk, although at therapeutic doses during short-term treatment, the risk of affecting the infant seems unlikely;

- pseudoephedrine is excreted in breast milk in large quantities and can cause adverse cardiovascular and neurological reactions in infants.

Contraindications

Hypersensitivity to the active substances (ibuprofen and pseudoephedrine hydrochloride), acetylsalicylic acid, other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients;

Patients with a history of hypersensitivity reactions (for example, bronchospasm, bronchial asthma, rhinitis, angioedema or urticaria) associated with the administration of acetylsalicylic acid or other NSAIDs;

Active gastrointestinal ulcer/hemorrhage or history of recurrent gastrointestinal ulcer/hemorrhage (two or more distinct episodes of proven ulceration or hemorrhage);

History of gastrointestinal bleeding or perforation related to previous NSAID treatment - patients with severe liver failure, severe renal failure, coronary disease or severe heart failure (NYHA Class IV classification);

• Hematopoietic disorders of unspecified etiology;
• Cerebrovascular hemorrhage or other active hemorrhage;
• Severe or therapeutically uncontrolled hypertension;
• Angina pectoris;
• Diabetes;
• Pheochromocytoma;
• Hyperthyroidism;
• Angle-closure glaucoma;
• Systemic lupus erythematosus;
• Hyperplasia of the prostate;
• Epilepsy;
• Concomitant administration with monoamine oxidase inhibitors (MAOIs) or within two weeks of stopping therapy with an MAOI;
• Children under 12 years of age and weighing under 40 kg;
• Last trimester of pregnancy.

Presentation : 20 tablets